Sangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Sangamo Therapeutics is set to announce its Q2 2025 earnings on August 5th, with analysts forecasting a loss of ($0.07) per share and revenue of $31.68 million.
• The company reported a significant miss in its last earnings release, with a loss of ($0.14) per share and revenue of $6.44 million compared to expectations of ($0.11) EPS and $7.90 million in revenue.
• Analyst ratings for Sangamo's stock vary, with one sell, two holds, and four buy ratings; the average target price is $4.50, down from prior estimates.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $31.68 million for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. The company had revenue of $6.44 million for the quarter, compared to analyst estimates of $7.90 million. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $0.56. 4,196,994 shares of the company were exchanged, compared to its average volume of 6,044,647. Sangamo Therapeutics has a twelve month low of $0.41 and a twelve month high of $3.18. The firm's 50-day simple moving average is $0.51 and its two-hundred day simple moving average is $0.75. The firm has a market cap of $130.95 million, a PE ratio of -1.44 and a beta of 1.23.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on SGMO shares. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.